Immune checkpoint inhibitors (ICIs) are monoclonal antibodies promoting the activation of the immune system against cancer. Molecules using monoclonal antibodies against the cytotoxic T lymphocyte-associated protein 4 (CTLA-4), such as ipilimumab, and against the programmed cell death 1 receptor (PD-1), such as nivolumab or pembrolizumab, have aide
1104 Reached
Complicated case of Osteoarthritis
1849 Reached2 Comments3 Likes
Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Resistant Thyrotoxicosis in Pregnancy
1335 Reached4 Comments2 Likes
Study to Test Tofacitinib Efficacy for Psoriatic Arthritis
446 Reached2 Comments4 Likes